XXXX -associated mortality: a systematic review and meta-analysis of the literature.

@entity1 @entity6838 @entity712 @entity955
UNASSIGNED: There are conflicting data regarding the effect of @entity6838 use on mortality in @entity1 with @entity955 ( @entity955 ) or with @entity712 ( @entity712 ). The aim of this meta-analysis was to provide detailed analysis of the currently available study reports. We performed a MEDLINE and a COCHRANE search (1993-2014) of the English literature dealing with the effects of @entity6838 on all-cause-mortality in subjects with @entity955 or @entity712 . Only full-sized articles published in peer-reviewed journals were considered for this meta-analysis. A total of 19 reports were identified. Nine reports dealt with @entity955 @entity1 , seven with @entity1 suffering from @entity712 , and three with both clinical conditions. Based on the analysis of adjusted mortality results of all 19 studies comprising 326 426 @entity1 , @entity6838 use was associated with an increased relative risk of all-cause mortality [Hazard ratio (HR) 1.21, 95% confidence interval (CI), 1.07 to 1.38, P < 0.01]. Compared with subjects not receiving glycosides, @entity6838 was associated with a 29% increased mortality risk (HR 1.29; 95% CI, 1.21 to 1.39) in the subgroup of publications comprising 235 047 @entity955 @entity1 . Among 91.379 @entity712 @entity1 , @entity6838 -associated mortality risk increased by 14% (HR 1.14, 95% CI, 1.06 to 1.22). The present systematic review and meta-analysis of all available data sources suggest that @entity6838 use is associated with an increased mortality risk, particularly among @entity1 suffering from @entity955 .
